This is a working overview of Mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-11. Anything still debated is marked as such rather than presented as settled.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
=== Recognition === In 2020, FutureFeed won a Food Planet Prize worth USD $1 million. FutureFeed was also shortlisted for the 2021 Eureka Prize in the Applied Environmental Research category. FutureFeed were named winners of the 2023 Bloomberg NEF Pioneers Award and many of its licensees raised further capital, won major industry awards and secured large commercial contracts on the back of production plans.
=== Mass spectrometry === Quantitative mass spectrometry (MS) (or quantitative proteomics) can be used to discover RNA-binding proteins (RBPs) bound to RNA. Labeling MS methods involve the differential use of stable isotope labels or chemical tagging of proteins in samples and controls. This is used to obtain enrichment scores and true binding partners through the ratio of labeled peptides. Label-free MS methods are able to identify proteins in samples and controls. In order to distinguish true binding partners for nonspecific proteins, analytical tools used alongside spectral count data from non-quantitative MS are used to score the probability of a true RBP-RNA interaction
Whitney Halberstram (Max Minghella) is the enigmatic co-founder and CFO of payment processing startup Tender, which he launches with college friend Jonah Atterbury. An American who claims to have grown up in poverty, Whitney frequently alters details about his background depending on his audience. He pivots Tender away from pornography and gambling clients toward banking, forcing Jonah out and installing himself as interim CEO. Whitney has a one-night stand with Harper and befriends Yasmin, who introduces him to Labour MP Jennifer Bevan for regulatory leverage in exchange for securing her husband Henry Muck a role at Tender. Whitney appoints Henry CEO to leverage his aristocratic connections and develops a sexual fixation on him. After learning Harper is shorting Tender and working with journalist James Dycker to investigate its African operations, Whitney and Yasmin move to discredit Dycker in print; Whitney then promotes Yasmin to head of communications. After Harper publicly reveals that Tender falsified profits in Africa, the company’s stock drops sharply. Whitney is shown to be under pressure from Russian intelligence interests using Tender to collect UK consumer data. He persuades EMEA CFO Tony Day not to act as a whistleblower and proposes a hostile takeover of Pierpoint to delay scrutiny from auditors, falsely claiming he already owns a stake. He travels to New York with Henry for Pierpoint’s AGM but later attempts to flee, having secured a fake Lithuanian passport and hired a Japanese jōhatsu firm to facilitate his disappearance.
According to Thomas Molloy, writing in the Irish Independent, "It had no qualms about selling drink to Catholics but it did everything it could to avoid employing them until the 1960s." Guinness thought they brewed their last porter in 1973. In the 1970s, following declining sales, the decision was taken to make Guinness Extra Stout more "drinkable". The gravity was subsequently reduced, and the brand was relaunched in 1981. Pale malt was used for the first time, and isomerised hop extract began to be used. In 2014, two new porters were introduced: West Indies Porter and Dublin Porter. Guinness acquired The Distillers Company in 1986. This led to a scandal and criminal trial concerning the artificial inflation of the Guinness share price during the takeover bid engineered by the chairman, Ernest Saunders. A subsequent £5.2 million success fee paid to an American lawyer and Guinness director, Tom Ward, was the subject of the case Guinness plc v Saunders, in which the House of Lords declared that the payment had been invalid. In the 1980s, as the IRA's bombing campaign spread to London and the rest of Britain, Guinness considered scrapping the harp as its logo. In 1997 the company merged with Grand Metropolitan to form Diageo. The company was maintained as a separate entity within Diageo and has retained the rights to the product and all associated trademarks of Guinness.
=== Society === Little is revealed of the Combine's activities outside of Earth, but dialogue in Half-Life 2 states that they control worlds of various dimensions inhabited by a range of species. The Combine occupation of Earth is shown to be a brutal totalitarian police state. In City 17, an Eastern European city, Civil Protection units routinely conduct searches of apartment blocks, interrogating human citizens, and engaging in wanton police brutality. The military Overwatch forces of the Combine attack human resistance bases in an effort to further solidify their authority in the urban centers. Human citizens are clad in blue uniforms, living in designated apartment blocks and move around to different cities or locales in passenger trains by the Combine's will. Vortigaunts, enemy alien creatures from Half-Life, have also been enslaved, and are observed in various professions such as janitors. According to Half-Life 2: Raising the Bar, the Combine are draining Earth's oceans and resources to be used on other Combine worlds. The heart of the Combine's command over Earth in Half-Life 2 is the Citadel, a large tower constructed by them which reaches both tens of thousands of feet (several or several tens of kilometres) into the sky and deep underground. Located within City 17, the Citadel serves as the Combine's headquarters on Earth, housing Combine Advisors and the office of Earth's administrator, Dr. Wallace Breen. Breen, a puppet ruler, is frequently seen on large screens around the city on which he spreads propaganda and makes announcements.
Sources: en.wikipedia.org
== History == FNDC5 was first discovered in 2002 during a genome search for fibronectin type III domains and independently, in a search for peroxisomal proteins. The ectodomain was proposed to be cleaved to give a soluble peptide hormone named irisin. Separately it was proposed that irisin is secreted from muscle in response to exercise, and may mediate some beneficial effects of exercise in humans and the potential for generating weight loss and blocking diabetes has been suggested. Others questioned these findings. A 2021 review highlights new discoveries of irisin in brain function and bone remodeling, but criticizes all studies using commercial antibody assays to measure irisin concentrations. It also raises a question of how an exercise hormone could arise in evolution. Shortly afterwards, a study using FNDC5 knock-out mice as well as artificial elevation of circulating irisin levels showed that irisin confers beneficial cognitive effects of physical exercise and that it can serve an exercise mimetic in mice. This regulatory system is therefore investigated for potential interventions to improve cognitive function or alleviate Alzheimer's disease.
During 1962, SWAPO had emerged as the dominant nationalist organisation for the Namibian people. It co-opted other groups such as the South West Africa National Union (SWANU), and later in 1976 the Namibia African People's Democratic Organisation. SWAPO used guerrilla tactics to fight the South African Defence Force. On 26 August 1966, the first major clash of the conflict took place, when a unit of the South African Police, supported by the South African Air Force, exchanged fire with SWAPO forces. This date is generally regarded as the start of what became known in South Africa as the Border War. One important factor in the fight for independence was the 1971-72 Namibian contract workers strike, which fought for the elimination of the contract labour system and independence from South Africa. An underlying goal was the promotion of independence under SWAPO leadership. In 1973, the United Nations General Assembly recognised SWAPO as the 'sole legitimate representative' of Namibia's people. The Norwegian government began giving aid directly to SWAPO in 1974. The country of Angola gained its independence on 11 November 1975 following its war for independence. The leftist Popular Movement for the Liberation of Angola (MPLA), supported by Cuba and the Soviet Union, came to power. In March 1976, the MPLA offered SWAPO bases in Angola for launching attacks against the South African military.
During World War II, German bombers would attack at night to evade British defenses. In order to keep the 1939 invention of a new on-board Airborne Intercept Radar system secret from Germany, the British Ministry of Information told newspapers an unproven claim that the nighttime defensive success of Royal Air Force pilots was due to a high dietary intake of carrots rich in β-carotene, successfully convincing many people. In 1967, George Wald shared the Nobel Prize in Physiology and Medicine for his work on chemical visual processes in the eye. Wald had demonstrated in 1935 that photoreceptor cells in the eye contain rhodopsin, a chromophore composed of the protein opsin and 11-cis-retinal. When struck by light, 11-cis-retinal undergoes photoisomerization to all-trans-retinal and via signal transduction cascade send a nerve signal to the brain. The all-trans-retinal is reduced to all-trans-retinol and travels back to the retinal pigment epithelium to be recycled to 11-cis-retinal and reconjugated to opsin. Wald's work was the culmination of nearly 60 years of research. In 1877, Franz Christian Boll identified a light-sensitive pigment in the outer segments of rod cells of the retina that faded/bleached when exposed to light, but was restored after light exposure ceased. He suggested that this substance, by a photochemical process, conveyed the impression of light to the brain.
Often, when British allies attempted military actions within several dozen miles or so of the sea, the Royal Navy would arrive, land troops and supplies, and aid the coalition's land forces in a concerted operation. Royal Navy ships even provided artillery support against French units when fighting strayed near enough to the coastline. The ability and quality of the land forces governed these operations. For example, when operating with inexperienced guerrilla forces in Spain, the Royal Navy sometimes failed to achieve its objectives because of the lack of manpower that the Navy's guerrilla allies had promised to supply.
Sources: en.wikipedia.org
Oxford were strong pre-race favourites, having won 16 of the last 17 races. Cambridge won the toss and elected to start from the Surrey station. Two minutes after the start, and in cold, overcast conditions, Cambridge's cox Martin Haycock was level with Oxford's Jo Michels who occupied the number two seat in the Dark Blue boat. Responding to a call to push on, Cambridge were clear upon reaching the Mile Post in record time, and moved in front of Oxford. Further record times were set as the Light Blues passed under Hammersmith Bridge and by Chiswick Steps before they passed the finishing post 3+1⁄2 lengths clear in 17 minutes. It was Cambridge's first victory since the 1986 race and just their second victory in eighteen years. The winning time was the fourth fastest in the history of the event, surpassed only by Oxford in the 1991, 1984 and 1976 races, and was Cambridge's fastest time ever. Cambridge's victory prevented the overall score from being levelled for the first time since 1929. In the reserve race, Cambridge's Goldie won by nine lengths over Isis, their sixth victory in seven years. Cambridge won the 48th Women's Boat Race by 4+1⁄2 lengths in a time of 6 minutes and 10 seconds, their fourth victory in five years.
=== Muscle involvement === Diagnosing MCTD involves identification of inflammatory myopathy that is histologically and clinically identical to polymyositis (PM). The majority of persons with MCTD do not experience clinical weakness. People with MCTD typically have mild myositis, with normal muscle enzymes and electromyographic results. Some people may be completely asymptomatic. Myositis can be severe and difficult to differentiate from conventional dermatomyositis. Myalgia is a prevalent complaint among patients with MCTD.
More severe side-effects may include respiratory depression (decreased breathing), seizure, psychosis, elevated heart rate and blood pressure, trouble sleeping, and liver injury. Addiction is a possible risk with regular use: when use is stopped, withdrawal symptoms may occur. Serious toxicity is relatively rare and generally appears at high doses or when kratom is used with other substances. A small number of deaths have been connected to the use of kratom, most commonly when mixed with other substances. As of 2018, kratom is a controlled substance in 16 countries. Some countries, like Indonesia and Thailand, have recently moved toward regulated legal production for medical use. There is growing international concern about a possible threat to public health from kratom use. In some jurisdictions its sale and importation have been restricted, and several public health authorities have raised alerts.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.